A dual-blind clinical trial of the c-Abl inhibitor nilotinib failed to show its clinical efficacy in patients with PD [35, 36], which is likely a result of incomplete inhibition of c-Abl activation [37]. The gene discussed is ABL1; the disease is Parkinson disease.